Market Entry of Advanced Wound Care Products Set to Change Treatment Landscape
Over the next five years, the DFU market is expected to see significant changes. In the wound-healing segment of the market, Macrocure's CureXcell and Derma Sciences' DSC127 have the most favorable clinical attributes, as clinical trial data are already available for both drugs, from post-marketing studies involving CureXcell in Israel, where it is already marketed, and from a Phase II trial of DSC127.
In terms of commercial attractiveness, CureXcell's developer, Macrocure, will struggle due to a lack of experience in the wound care market. Despite this setback, KOLs interviewed by GlobalData still believe that CureXcell is the most unique and promising of the late-stage pipeline agents currently in development.
If Macrocure is able to obtain a licensing partner to aid in the development and marketing of its product, CureXcell would be an ideal therapy for chronic hard-to-heal DFUs.